What Is Redhill Biopharma Ltd. (RDHL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Redhill Biopharma Ltd.'s intrinsic value is estimated at a composite fair value of $1.87. At a current market price of $0.74, 8 of 10 active valuation models identify upside potential, projecting an average implied return of +152.1%. Notably, EPV sees the most upside at +499.5% (fair value: $4.46), while ML-RIV is the most conservative at -96.6% ($0.03). The spread between these extremes — +596.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About RDHL?
10 of 13 models are currently active for RDHL. Of these, 8 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates RDHL's intrinsic value at $0.51, implying -31.5% downside from the current price. See which stocks rank higher →
How Does RDHL Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, RDHL ranks #237 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Redhill Biopharma Ltd., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.
Is RDHL a Value Trap?
CirclFi's Value Trap algorithm assigns RDHL a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Redhill Biopharma Ltd.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Redhill Biopharma Ltd. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +596.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RDHL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RDHL's 10 active models, average confidence is 17%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad